Published in Arch Otolaryngol Head Neck Surg on May 01, 2011
STAT inhibitors for cancer therapy. J Hematol Oncol (2013) 1.16
Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. Mol Cancer Ther (2013) 1.08
Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes. Int J Nanomedicine (2011) 0.95
In vitro and in vivo antitumoral effects of combinations of polyphenols, or polyphenols and anticancer drugs: perspectives on cancer treatment. Int J Mol Sci (2015) 0.92
Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling. Br J Cancer (2015) 0.89
JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth. Neoplasia (2015) 0.89
Biological and therapeutic activities, and anticancer properties of curcumin. Exp Ther Med (2015) 0.86
Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers. Oncotarget (2015) 0.82
Curcuma Contra Cancer? Curcumin and Hodgkin's Lymphoma. Cancer Growth Metastasis (2013) 0.78
Cytotoxic Effect of Coscinium fenestratum on Human Head and Neck Cancer Cell Line (HN31). Evid Based Complement Alternat Med (2015) 0.75
Anti-Lung Cancer Activity of the Curcumin Analog JZ534 In Vitro. Biomed Res Int (2015) 0.75
Integrative Medicine in Head and Neck Cancer. Otolaryngol Head Neck Surg (2016) 0.75
STATs and gene regulation. Science (1997) 16.55
The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer (2007) 12.38
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med (2004) 8.60
STATs in oncogenesis. Oncogene (2000) 8.60
Transcription factors as targets for cancer therapy. Nat Rev Cancer (2002) 7.27
Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science (1995) 6.28
Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res (2002) 5.84
Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci (2008) 4.24
Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol (1998) 4.09
Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A (2000) 3.44
Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci (2008) 3.16
Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck (2010) 2.51
Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res (2002) 2.41
Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem (1994) 2.36
STAT signaling in head and neck cancer. Oncogene (2000) 2.19
Targeting Stat3 in cancer therapy. Anticancer Drugs (2005) 2.13
Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res (2010) 1.91
A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol (1992) 1.84
Cellular and molecular determinants of cisplatin resistance. Eur J Cancer (1998) 1.82
STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ (2002) 1.69
Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res (1988) 1.61
P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck (2003) 1.40
A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas. Int J Cancer (2008) 1.35
Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis (2009) 1.30
Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma. Oncol Rep (2010) 1.28
Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane). Int J Cancer (2006) 1.12
Activation of Stat-3 as one of the early events in tobacco chewing-mediated oral carcinogenesis. Cancer (2002) 1.10
Therapeutic suppression of constitutive and inducible JAK\STAT activation in head and neck squamous cell carcinoma. J Exp Ther Oncol (2009) 0.96
Activation of signal transducers and activators of transcription 3 and overexpression of its target gene CyclinD1 in laryngeal carcinomas. Laryngoscope (2008) 0.93
Signal transducers and activators of transcription 3 up-regulates vascular endothelial growth factor production and tumor angiogenesis in head and neck squamous cell carcinoma. Oral Oncol (2006) 0.88
Chemotherapy of squamous cell carcinoma of head and neck: the future is now. Ann Oncol (1996) 0.86
EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol (2008) 5.46
Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol (2008) 3.55
A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci U S A (2005) 3.46
Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2002) 3.39
Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck (2010) 2.76
Targeted gold nanoparticles enable molecular CT imaging of cancer. Nano Lett (2008) 2.55
Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck (2010) 2.51
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A (2013) 2.49
Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck (2007) 2.49
Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol (2010) 2.41
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res (2011) 2.31
Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res (2010) 2.11
Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys (2004) 2.00
Lean management in academic surgery. J Am Coll Surg (2012) 1.97
Neuroendocrine neoplasms of the larynx: an overview. Head Neck (2009) 1.92
Clinical predictors of quality of life in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg (2004) 1.91
Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res (2010) 1.91
A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res (2006) 1.85
Merkel cell carcinoma: critical review with guidelines for multidisciplinary management. Cancer (2007) 1.83
Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun (2005) 1.76
Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. Mol Cancer Ther (2005) 1.70
A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia (2010) 1.70
The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer (2007) 1.64
Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res (2013) 1.64
STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res (2011) 1.63
Intramolecular diels-alder/1,3-dipolar cycloaddition cascade of 1,3,4-oxadiazoles. J Am Chem Soc (2006) 1.63
Cutaneous head and neck basal and squamous cell carcinomas with perineural invasion. Oral Oncol (2012) 1.55
Multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors. J Biol Chem (2012) 1.55
In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res (2004) 1.55
(-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. Neoplasia (2006) 1.55
Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation. Proc Natl Acad Sci U S A (2013) 1.49
Identification and characterization of choline transporter-like protein 2, an inner ear glycoprotein of 68 and 72 kDa that is the target of antibody-induced hearing loss. J Neurosci (2004) 1.48
UM-SCC-104: a new human papillomavirus-16-positive cancer stem cell-containing head and neck squamous cell carcinoma cell line. Head Neck (2011) 1.45
P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck (2003) 1.40
Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res (2012) 1.39
Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation. Laryngoscope (2002) 1.35
Rap1GAP promotes invasion via induction of matrix metalloproteinase 9 secretion, which is associated with poor survival in low N-stage squamous cell carcinoma. Cancer Res (2008) 1.35
Advances and applications of oral cancer basic research. Oral Oncol (2011) 1.33
Chemo-IMRT of oropharyngeal cancer aiming to reduce dysphagia: swallowing organs late complication probabilities and dosimetric correlates. Int J Radiat Oncol Biol Phys (2011) 1.33
Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. Head Neck (2002) 1.32
Curcumin is a potent DNA hypomethylation agent. Bioorg Med Chem Lett (2008) 1.31
Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer. Arch Otolaryngol Head Neck Surg (2010) 1.31
Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. Int J Radiat Oncol Biol Phys (2007) 1.31
Genome-wide methylation and expression differences in HPV(+) and HPV(-) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics (2011) 1.29
Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer. World J Surg (2003) 1.28
Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. J Biol Chem (2010) 1.28
The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol Cancer (2010) 1.27
Rap1GAP inhibits tumor growth in oropharyngeal squamous cell carcinoma. Am J Pathol (2006) 1.26
Molecular profiling and the identification of genes associated with metastatic oral cavity/pharynx squamous cell carcinoma. Arch Otolaryngol Head Neck Surg (2004) 1.23
HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans. Head Neck (2010) 1.23
Rap1A and rap1B ras-family proteins are prominently expressed in the nucleus of squamous carcinomas: nuclear translocation of GTP-bound active form. Oncogene (2003) 1.22
Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol Cancer Ther (2008) 1.22
Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B. J Biol Chem (2002) 1.21
Functional assessment using Constant's Shoulder Scale after modified radical and selective neck dissection. Head Neck (2002) 1.21
Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer (2007) 1.20
Surgical margins in head and neck cancer: a contemporary review. Head Neck (2012) 1.19
Pectoralis major myocutaneous flap vs revascularized free tissue transfer: complications, gastrostomy tube dependence, and hospitalization. Arch Otolaryngol Head Neck Surg (2004) 1.19
Matted nodes: poor prognostic marker in oropharyngeal squamous cell carcinoma independent of HPV and EGFR status. Head Neck (2012) 1.18
Design, synthesis, and studies of small molecule STAT3 inhibitors. Bioorg Med Chem Lett (2007) 1.18
HRP2 determines the efficiency and specificity of HIV-1 integration in LEDGF/p75 knockout cells but does not contribute to the antiviral activity of a potent LEDGF/p75-binding site integrase inhibitor. Nucleic Acids Res (2012) 1.18
Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion. Laryngoscope (2009) 1.17
Features predicting sentinel lymph node positivity in Merkel cell carcinoma. J Clin Oncol (2011) 1.16
Delineating genetic pathways of disease progression in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg (2003) 1.14
The A128T resistance mutation reveals aberrant protein multimerization as the primary mechanism of action of allosteric HIV-1 integrase inhibitors. J Biol Chem (2013) 1.14
STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH⁺/CD133⁺ stem cell-like human colon cancer cells. Biochem Biophys Res Commun (2011) 1.13
Bcl-2 protects endothelial cells against gamma-radiation via a Raf-MEK-ERK-survivin signaling pathway that is independent of cytochrome c release. Cancer Res (2007) 1.12
The pattern of failure after reirradiation of recurrent squamous cell head and neck cancer: implications for defining the targets. Int J Radiat Oncol Biol Phys (2009) 1.10
Disability in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg (2004) 1.10
Stat3 upregulates MEK5 expression in human breast cancer cells. Oncogene (2004) 1.10
Characterization of STAT3 activation and expression in canine and human osteosarcoma. BMC Cancer (2009) 1.10
Infiltrating lymphocytes and human papillomavirus-16--associated oropharyngeal cancer. Laryngoscope (2012) 1.09
Expression of p14ARF overcomes tumor resistance to p53. Cancer Res (2002) 1.06
The gene ratios c-MYC:cyclin-dependent kinase (CDK)N2A and CCND1:CDKN2A correlate with poor prognosis in squamous cell carcinoma of the head and neck. Clin Cancer Res (2003) 1.06
Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck (2002) 1.06
Paranasal sinus malignancies: an 18-year single institution experience. Laryngoscope (2002) 1.05
Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma. Mod Pathol (2007) 1.05
A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells. Mol Cancer (2010) 1.05